{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:36:13Z","timestamp":1785576973757,"version":"3.56.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T00:00:00Z","timestamp":1368662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0064622","type":"journal-article","created":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T21:10:11Z","timestamp":1368738611000},"page":"e64622","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Anti-Tuberculosis Drug Induced Hepatotoxicity among TB\/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study"],"prefix":"10.1371","volume":"8","author":[{"given":"Alima","family":"Hassen Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tefera","family":"Belachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemeshet","family":"Yami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wubeante Yenet","family":"Ayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,5,16]]},"reference":[{"key":"ref1","unstructured":"WHO (2011) Global tuberculosis control. Geneva."},{"key":"ref2","unstructured":"Kaplan JE, Benson C, Holmes KK, Brooks JT, Masur H (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. 1\u2013207 p."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600 mg\/day versus efavirenz 800 mg\/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results","volume":"20","author":"W Manosuthi","year":"2006","journal-title":"AIDS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2334-9-42","article-title":"HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study","volume":"9","author":"JK Varma","year":"2009","journal-title":"BMC Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccm.2005.02.002","article-title":"Issues in the management of HIV related tuberculosis","volume":"26","author":"W Burman","year":"2005","journal-title":"Clin Chest Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-Induced Hepatotoxicity","volume":"349","author":"WM Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1164\/ajrccm.164.7.2109052","article-title":"Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers","volume":"164","author":"WJ Burman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/COH.0b013e328122dbaa","article-title":"Antiretroviral therapy-induced liver alterations","volume":"2","author":"U Walker","year":"2007","journal-title":"Curr Opin HIV AIDS"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1086\/518655","article-title":"Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome","volume":"196","author":"H McIlleron","year":"2007","journal-title":"J Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1371\/journal.pone.0001809","article-title":"Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients","volume":"3","author":"Yimer Getnet","year":"2008","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug induced hepatotoxicity: Concise upto date review","volume":"23","author":"A Tostmann","year":"2008","journal-title":"J Gastroen Heaptol"},{"key":"ref12","first-page":"163","article-title":"Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome","volume":"17","author":"H Khalili","year":"2009","journal-title":"DARU"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/pds.1468","article-title":"Adverse reactions of antituberculosis drugs in hospitalized patients: incidence, severity and risk factors","volume":"16","author":"MR Javadi","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e21836","DOI":"10.1371\/journal.pone.0021836","article-title":"Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China","volume":"6","author":"P Shang","year":"2011","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e27810","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic and pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients","volume":"6","author":"G Yimer","year":"2011","journal-title":"PLoS ONE"},{"key":"ref16","first-page":"688","article-title":"Prevalence and risk factors of antituberculosis drug-induced hepatitis in Malaysia","volume":"49","author":"OA Marzuki","year":"2008","journal-title":"Singapore Med J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1345\/aph.1D525","article-title":"Incidence of hepatotoxicity due to antitubercular medicines and asssessment of risk factors","volume":"38","author":"R Shakya","year":"2004","journal-title":"Ann Pharmacother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4038\/cmj.v51i1.1369","article-title":"Anti-tuberculosis drug induced hepatitis -a Sri Lankan experience","volume":"51","author":"WV Senaratne","year":"2006","journal-title":"Ceylon Medical Journal"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-008-9085-y","article-title":"A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases","volume":"2","author":"HA Makhlouf","year":"2008","journal-title":"Hepatol Int"},{"key":"ref20","first-page":"78","article-title":"Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment","volume":"11","author":"E Pukenyte","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1590\/S0102-311X2012000400009","article-title":"Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis","volume":"28","author":"MF Lima","year":"2012","journal-title":"Cad Saude Publica"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0041-3879(86)90003-6","article-title":"Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide","volume":"67","author":"R Parthasarathy","year":"1986","journal-title":"Tubercle"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment","volume":"166","author":"SK Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"ref24","first-page":"87","article-title":"A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose","volume":"3","author":"SS Kalsi","year":"2011","journal-title":"Emergency Medicine"},{"key":"ref25","unstructured":"NIN (1989) National Institute of Nutrition. BMI and mortality rate-a 10 year prospective study. National Institute of Nutrition Annual Report: 1\u201313."},{"key":"ref26","first-page":"84","article-title":"Standard antituberculosis drug induced hepatotoxicity: Do the risk factors matter?","volume":"9","author":"K Khoharo","year":"2010","journal-title":"JLUMHS"},{"key":"ref27","first-page":"167","article-title":"Antituberculous drug-induced liver injury: current perspective","volume":"32","author":"H Devarbhavi","year":"2011","journal-title":"Tropical Gastroenterology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2165\/00002018-199615060-00004","article-title":"Hepatotoxicity of antitubercular treatments","volume":"15","author":"F Durand","year":"1996","journal-title":"Drug Safety"},{"key":"ref29","first-page":"65","article-title":"The management of anti-tuberculosis drug-induced hepatotoxicity","volume":"5","author":"K Tahaoglu","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study","volume":"51","author":"JN Pande","year":"1996","journal-title":"Thorax"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/pds.1468","article-title":"Adverse reactions of antituberculosis drugs in hospitalized patients: incidence, severity and risk factors","volume":"16","author":"MR Javadi","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.phrs.2004.10.009","article-title":"Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment","volume":"51","author":"M Sharifzadeh","year":"2005","journal-title":"Pharmacol Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","article-title":"Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs","volume":"20","author":"D Marks","year":"2009","journal-title":"Int J STD AIDS"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0064622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T22:16:01Z","timestamp":1563056161000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0064622"}},"subtitle":[],"editor":[{"given":"Miguel","family":"Santin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,16]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0064622","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,16]]}}}